摘要
目的探讨急性心肌梗死合并心房颤动患者使用胺碘酮治疗的临床疗效及安全性。方法选取2013年5月至2016年5月于我院接受治疗的78例急性心肌梗死合并心房颤动患者为研究对象,将其随机分为对照组和治疗组各39例,对照组患者给予普罗帕酮治疗,治疗组给予胺碘酮,比较两组患者24 h内窦性心律恢复情况,30 d内窦性心律维持及不良反应的发生情况。结果治疗后,治疗组24 h内心房颤动在不同时间段转复率、总转复率、心房颤动转复后30 d内窦性心律维持率明显高于对照组,差异有统计学意义(P<0.05);治疗组不良反应发生率明显低于对照组,差异有统计学意义(P<0.01)。结论急性心肌梗死合并心房颤动患者使用胺碘酮治疗临床效果显著,值得临床推广应用。
Objective To investigate the clinical value of amiodarone on patients with acute myocardial infarction complicated with atrial fibrillation. Methods Seventy-eight cases of acute myocardial infarction complicated with atrial fibrillation patients in our hospital from May 2013 to May 2016 were selected and devided into control group （propafenone） and treatment group （amiodarone）, with 39 cases in each group. The recovery of sinus rhythm within 24 h, the maintenance of sinus rhythm and the occurrence of adverse reactions in 30 d were detected and compared. Results The recovery rate of 24 h heart atrial fibrillation and the maintenance rate of sinus rhythm in 30 d in the treatment group were significantly higher than those in the control group, the differences showed statistical significance （P〈0.05）. The adverse reaction rate in the treatment group was significantly lower than that in the control group （P〈0.01）. Conclusion Amiodarone in the treatment of patients with acute myocardial infarction complicated with atrial fibrillation has significant clinical value, which is worthy of clinical application.
出处
《临床医学研究与实践》
2017年第1期19-20,共2页
Clinical Research and Practice
关键词
急性心肌梗死
心房颤动
胺碘酮
acute myocardial infarction
atrial fibrillation
amiodarone
